— Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047)

— Median overall survival of 26.09 months; 86.7% of patients alive at six months

— Five of 24 patients remain on treatment, with one partial response ongoing beyond 114 days

— No major toxicities reported across the cohort; adverse events predominantly low-grade

— Company to host investor conference call and webcast today at 8:30 a.m. Eastern Time